checkpoint protein inhibitor antibody cpi include cytotox tlymphocyteassoci antigen inhibitor ipilimumab tremelimumab program cell death pathwayprogram ligand pembrolizumab nivolumab durvalumab atezolizumab enter routine practice treatment mani cancer improv outcome patient treat future although lead adverse event ae le frequent chemotherapy use require intent care unit admins case sever immunerel ira more particularly late poorly document high level suspicion maintain receive intensivist war genre known complex appropri manga nevertheless multidisciplinary collar remain essential diagnosis review describe relay electron supplementary mater online version article sx contain avail author user 